RDT is going to become the norm. Personalized dosing based on levels on many other antimicrobials, like beta-lactams, that we don’t currently do regularly

😹

Repetition. I am constantly giving the same recommendation and showing the new evidence to make it the “new normal”.

I think it’s important to make sure providers understand where certain RDT (nares) has been studied and the limitations of those tools (meningitis PCR)

We’ve done a lot of work at my system on improving access to dalbavancin. It’s been a lot of work to get the drug covered for a lot of our patients